PR
PRME.US Prime Medicine, Inc. Common Stock
- Market cap
- USD 856M
- P/E
- -
- P/B
- 112.05x
- ROE
- -2,058.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PRME.US undervalued?
Graham numberThe Graham number of Prime Medicine, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Prime Medicine, Inc. Common Stock fundamental analysis
No fundamental analysis for Prime Medicine, Inc. Common Stock yet.
Prime Medicine, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Prime Medicine, Inc. Common Stock
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-A…
Full company profilePrime Medicine, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Prime Medicine, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 5.21M | 0.00 | 5.21M | 0.00 | 2.98M | 4.63M | 8.30M |
| Gross Profit | -2.76M | 2.23M | -4.86M | -12.0M | -4.65M | 2.98M | -2.69M | 3.48M |
| Operating Income | -2.17M | -932K | -84.5M | -117M | -205M | -202M | -208M | -178M |
| EBITDA | 3.99M | -889K | -165M | -121M | -187M | -190M | -196M | -166M |
| Net Income | -2.53M | -3.41M | -165M | -122M | -198M | -196M | -201M | -174M |
| EPS | -0.03 | -0.04 | -1.73 | -1.25 | -2.18 | -1.65 | -1.35 | -0.98 |
| Balance Sheet | ||||||||
| Total Assets | 8.70M | 54.8M | 302M | 360M | 194M | 298M | 343M | 214M |
| Total Liabilities | 7.31M | 21.3M | 62.3M | 44.0M | 60.8M | 144M | 222M | 205M |
| Shareholders' Equity | 1.39M | 33.5M | 240M | 316M | 133M | 153M | 121M | 8.44M |
| Cash & Short-term Investments | 8.65M | 53.3M | 270M | 294M | 122M | 190M | 178M | 61.2M |
| Total Debt | - | 17.5M | 10.4M | 28.7M | 13.6M | 40.8M | 116M | 110M |
| Cash Flow | ||||||||
| Operating Cash Flow | -1.33M | -5.54M | -34.1M | -132M | -165M | -123M | -163M | -161M |
| Capital Expenditure | 639K | 639K | 4.15M | 16.1M | 8.72M | 7.29M | 4.53M | 744K |
| Free Cash Flow | -1.97M | -6.18M | -38.2M | -148M | -174M | -130M | -167M | -161M |
| Ratios | ||||||||
| ROE | -182.1% | -10.2% | -69.0% | -38.5% | -148.9% | -127.9% | -166.4% | -2,058.8% |
| ROA | -29.1% | -6.2% | -54.8% | -33.8% | -102.2% | -65.8% | -58.7% | -81.2% |
| Net Profit Margin | - | -65.5% | - | -2,338.2% | - | -6,566.6% | -4,342.4% | -2,093.4% |
| Debt to Equity | - | 0.52x | 0.04x | 0.09x | 0.10x | 0.27x | 0.96x | 13.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Prime Medicine, Inc. Common Stock dividends
Prime Medicine, Inc. Common Stock has not paid dividends in the last 7 fiscal years.
Who owns Prime Medicine, Inc. Common Stock
- Insiders 17.01%
- Institutions 57.48%
- Public & others 25.51%
- Shares outstanding 223M
- Free float 107M
Top funds holding PRME.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARK Genomic Revolution ETF | 8.08M | 4.44% | +0.58% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 3.88M | 2.13% | +2.69% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.12M | 1.72% | 0.00% | Sep 2026 |
| ARK Venture D | 2.94M | 1.61% | +18.34% | Jul 2026 |
| iShares Russell 2000 ETF | 2.37M | 1.30% | 0.00% | Oct 2026 |
| Amova ARK Pstv Chg Innovt P JPY Acc | 2.32M | 1.28% | -3.52% | Sep 2026 |
| T. Rowe Price Small-Cap Stock | 1.21M | 0.67% | -0.57% | Sep 2026 |
| Fidelity Small Cap Index | 1.04M | 0.57% | +1.39% | Aug 2026 |
| T. Rowe Price Small-Cap Value | 995K | 0.55% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 774K | 0.43% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 739K | 0.41% | -0.19% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 724K | 0.40% | +1.13% | Sep 2026 |
| Selectra J. Lamarck Biotech A | 670K | 0.37% | 0.00% | Oct 2026 |
| T. Rowe Price Instl Small-Cap Stock | 650K | 0.36% | -16.95% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 632K | 0.35% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 576K | 0.32% | -0.38% | Sep 2026 |
| Vanguard Russell 2000 ETF | 548K | 0.30% | +1.25% | Sep 2026 |
| ARK Genomic Revolution ETF A USD Acc | 469K | 0.26% | 0.00% | Oct 2026 |
| JPM Thmtcs Gentc Thrps C2 dist USD | 348K | 0.19% | -0.83% | Sep 2026 |
| Vanguard Health Care ETF | 317K | 0.17% | +0.11% | Sep 2026 |
Top institutions holding PRME.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Alphabet Inc | 16.6M | 9.10% | 0.00% | Jun 2026 |
| BlackRock Inc | 9.60M | 5.28% | +12.94% | Jun 2026 |
| ARK Investment Management LLC | 8.35M | 4.59% | +33.65% | Jun 2026 |
| State Street Corp | 7.58M | 4.16% | +19.41% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 5.24M | 2.88% | -4.46% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.52M | 2.49% | +1.08% | Jun 2026 |
| Balyasny Asset Management LLC | 3.97M | 2.18% | -3.74% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.43M | 1.89% | +253.51% | Jun 2026 |
| Casdin Capital, LLC | 3.17M | 1.74% | 0.00% | Jun 2026 |
| Woodline Partners LP | 3.00M | 1.65% | +0.02% | Jun 2026 |
| UBS Group AG | 2.79M | 1.54% | -3.25% | Jun 2026 |
| Geode Capital Management, LLC | 2.71M | 1.49% | -1.14% | Jun 2026 |
| Sumitomo Mitsui Trust Group Inc | 2.41M | 1.33% | -17.95% | Jun 2026 |
| Amova Asset Management Americas, Inc | 2.41M | 1.32% | -18.15% | Jun 2026 |
| Citadel Advisors Llc | 2.05M | 1.13% | +510.82% | Jun 2026 |
| ADAR1 Capital Management LLC | 2.00M | 1.10% | +1.23% | Jun 2026 |
| FMR Inc | 1.76M | 0.97% | -0.43% | Jun 2026 |
| Two Sigma Investments LLC | 1.52M | 0.84% | -3.07% | Jun 2026 |
| Redmile Group, LLC | 1.39M | 0.76% | -12.65% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 1.24M | 0.68% | 0.00% | Jun 2026 |
Prime Medicine, Inc. Common Stock company profile
- Company name
- Prime Medicine, Inc. Common Stock
- Ticker
- PRME.US
- Exchange
- USA Stocks
- Listed since
- Oct 20, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 146
- Fiscal year end
- December
- Address
- 60 First Street, Cambridge, MA, United States, 02141
- Phone
- 617 465 0013
- Website
- primemedicine.com
About Prime Medicine, Inc. Common Stock
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Prime Medicine, Inc. Common Stock management
10- Mr. Jeffrey D. Marrazzo M.B.A., M.P.A.Executive Chair · born 1979
- Dr. Allan Reine M.D.CEO & Director · born 1975
- Dr. Ann L. Lee Ph.D.Chief Technical Officer · born 1962
- Dr. Andrew Anzalone M.D., Ph.D.Co-Founder & Head of Platform · born 1987
- Dr. David R. Liu Ph.D.Co-Founder & Member of Scientific Advisory Board
- Ms. Svetlana MakhniChief Financial Officer · born 1984
- Mr. Ryan E. Brown J.D.Chief Legal Officer · born 1979
- Ms. Niamh AlixChief Human Resources Officer
- Mr. Mohammed Asmal M.D., Ph.D.Chief Medical Officer
- Dr. Matthew J. Hawryluk M.B.A., Ph.D.Chief Business Officer · born 1979